Pfizer's Ibrance meets primary end point, stopping trial early

US pharma major Pfizer (NYSE: PFE) will stop its late-stage trial of Ibrance (palbociclib) early after hitting its primary endpoint.

The data, as assessed by an independent data monitoring committee, showed that the trial met the target of demonstrating an improvement in progression-free survival in certain patients with metastatic breast cancer. This data marks the “first randomized Phase III trial results” for Ibrance, a CDK 4/6 inhibitor.

The PALOMA-3 study was designed to assess the safety and efficacy of Ibrance in combination with AstraZeneca’s (LSE: AZN) Faslodex (fulvestrant) versus Faslodex versus placebo in patients with hormone receptor-positive, HER2-negative metastatic breast cancer following disease progression during or after endocrine therapy.